Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly ...
Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute and Heidelberg University ...
Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), ...
Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course. During a live event, Kristen M. Pettit, MD, associate professor of medicine at the ...
New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal. In this installment of this series, ‘The Future of Factor XIa ...
In these 2025 Advanced Life Support Guidelines, the American Heart Association provides comprehensive recommendations for the resuscitation and management of adults experiencing cardiac arrest, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results